Can Chemours (CC) Stay Undervalued As AI Cooling Expands?

Chemours stock has quietly had a tough run over the past few years, yet on broad valuation checks it still comes through as looking cheap. For investors trying to square a high value score with a long stretch of weak share returns, the question is whether the current price reflects too much pessimism or not enough caution.

• Over the past 3 years the Chemours share price has fallen 48.2%, which signals that sentiment around the business has been weak for an extended period.
• The move into AI data center cooling with new Opteon refrigerants can support revenue opportunities, while execution risk around new product adoption may limit how much value the market is willing to assign to that growth story.
• The broader checks lean cheap, with a high value score of 6 suggesting Chemours trades on the low side relative to its fundamentals and peer multiples.

The issue now is whether Chemours offers enough valuation upside to compensate for its history of weak long term returns and the risks around its newer growth bets.

Compare Chemours with other potential value ideas by scanning the 33 high quality undervalued stocks that screens for solid fundamentals and depressed valuations.

Does Chemours Look Undervalued on Sales?

The P/S ratio is a useful metric for Chemours because revenue is less affected by short-term earnings swings than metrics like the P/E ratio. On this measure, Chemours trades on a P/S of about 0.4x, which is well below the Chemicals industry average of 1.1x and also below the peer group at roughly 1.0x. A valuation framework that blends the company’s growth profile, margins, risk and scale indicates a fair P/S closer to 1.0x.

At the current P/S level, the share price reflects a sizeable discount relative to this framework for Chemours, even with the AI data center cooling products now included in the business narrative. The gap suggests the market is valuing the company’s sales at a materially lower level than those of typical sector peers.

On the P/S multiple, Chemours stock appears undervalued relative to both this tailored fair ratio and the broader Chemicals industry.

See what the numbers say about this price — find out in our valuation breakdown.

The Chemours Narrative: What Would Justify Today's Price?

Narratives pick up where Chemours' valuation puzzle leaves off by spelling out which growth, margin and earnings paths would need to play out for the stock to be worth materially more or materially less than today's price. They sit on Simply Wall St's Community page, and each one treats Chemours' fair value as a clear, testable thesis about the business that you can keep revisiting as new information comes through.

Community views on Chemours sit far apart, with one group leaning into refrigerant and litigation progress while another focuses on regulatory and product concentration risks.

Bull case: 24% undervalued

"Acceleration in regulatory-driven adoption of low global warming potential (GWP) refrigerants is boosting sustained demand for Chemours' Opteon franchise, recent strong net sales and high margins signal that continued market share gains and capacity expansions will drive robust revenue and EBITDA growth through and beyond the 2025 and 2026 transition periods..."

Read the full Bull Case to see why Chemours could be undervalued

Bear case: roughly fairly valued

"Increasing global regulation of PFAS and other hazardous materials could significantly restrict Chemours' addressable market for core fluorochemical products, leading to persistent headwinds for revenue growth and the potential for further legal and remediation liabilities, which would weigh directly on net earnings and future cash flow..."

Read the full Bear Case to see why Chemours could be overvalued

Do you think there's more to the story for Chemours? Head over to our Community to see what others are saying!

The Bottom Line

Chemours screens as undervalued on market multiples, yet the long stretch of weak 3 year returns shows investors are still uneasy about the story. The central question is whether the discount reflects temporary skepticism on refrigerant and data center opportunities or a lasting penalty for regulatory, litigation and product concentration risk. The investment case now largely turns on whether Chemours can turn its portfolio strengths into steadier earnings that eventually justify a higher multiple, or whether the stock proves to be a value trap in line with current market concerns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com